#LCSM Transcript
Healthcare social media transcript of the #LCSM hashtag.
– ().
See #LCSM Influencers/Analytics.
| Profile | Tweet |
|---|---|
 | NCI Cancer Stats @NCICancerStats Get the stats on #LungCancer by watching our new Did You Know? Video: https://t.co/MnrkjeW1f2 #LCSM |
 | #LCSM Chat @lcsmchat RT @JackWestMD: |
 | Angela Criswell @CriswellAngela RT @LCAorg: LCA’s Director of Science & Research, @JenniferCKing, recaps this year’s lung cancer science + research advances and what we can expect in 2018. Check it out! #lungcancer #LCSM #research >> https://t.co/btliTU5pSz https://t.co/lHEXtNSPBJ |
 | Janet Freeman-Daily @JFreemanDaily Evening, @JackWestMD! Good to see you moderating again. #lcsm |
 | Faces of Lung Cancer @LungCancerFaces Hi, Jack! Deana here in windy, sooty Los Angeles. #lcsm |
 | Naomi @ChancesR3 Naomi here from L.A. too. Hey D! #lcsm |
 | Brendon Stiles @BrendonStilesMD Hi! Skipping department holiday party to join! Although may be a bit in and out. Hope everyone is doing great! #lcsm |
| Faces of Lung Cancer @LungCancerFaces @ChancesR3 Hey you! How's the trial going? #lcsm |
| Janet Freeman-Daily @JFreemanDaily Hi Nay and Brendon! #lcsm |
 | Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Tim here #lcsm https://t.co/5BdMoKibgm |
| Faces of Lung Cancer @LungCancerFaces @BrendonStilesMD It must be one boring party... #lcsm |
| Faces of Lung Cancer @LungCancerFaces @TimAllenMDJD How is my favorite pathologist? #lcsm |
| #LCSM Chat @lcsmchat RT @JackWestMD: |
| Brendon Stiles @BrendonStilesMD Too many surgeons. RT @LungCancerFaces: @BrendonStilesMD It must be one boring party... #lcsm |
| Brendon Stiles @BrendonStilesMD Hi Tim! RT @TimAllenMDJD: Tim here #lcsm https://t.co/1moqVUuvbE |
| Brendon Stiles @BrendonStilesMD Hi Janet! Hi Nay! RT @JFreemanDaily: Hi Nay and Brendon! #lcsm |
| Janet Freeman-Daily @JFreemanDaily Janet here on the Washington Coast, grabbing the last bit of sun before the winter gray skies set in #lcsm https://t.co/Le93sr0fQ7 |
| Naomi @ChancesR3 @LungCancerFaces Wooh! 2 long days yesterday and today but good. 10 hours yesterday of observation, blood draws and blood pressure readings. We are in cycle 2 so he has had 2 doses of the study drug and 2 doses of immunotherapy. No appetite but so far things are ok. Scan and MRI in January. #lcsm |
 | Robert C. Doebele, MD, PhD @rdoebele LCSM hi #lcsm |
| Janet Freeman-Daily @JFreemanDaily Welcome @TimAllenMDJD! #lcsm |
| Brendon Stiles @BrendonStilesMD Here in NYC, reflecting on another great year for #LungCancer. As I tell patients, there has never been a better time to have the disease. BUT...we can do better. #lcsm |
| Janet Freeman-Daily @JFreemanDaily Hey @rdoebele! Welcome to #LCSM chat! Not your first, but it's been a while. |
| Robert C. Doebele, MD, PhD @rdoebele Hi from Denver, haven't been here in a while. Med Onc and translational researcher. #lcsm |
 | Nathan A. Pennell MD, PhD, FASCO @n8pennell Nate Pennell, oncologist from Cleveland here. I'll be in and out! #lcsm |
| Faces of Lung Cancer @LungCancerFaces @ChancesR3 Finger crossed, sweetie. You both need a break. Here's to a brighter 2018. #lcsm |
 | Geri Massa @GeriGerim13 Hi y’all, Geri in Louisiana here #lcsm https://t.co/cyBKiZVSQG |
| Janet Freeman-Daily @JFreemanDaily Forgot to mention I'm a #lungcancer patient/activist. Nobody knew that, right? ;) #lcsm |
 | Bob Steele @steele_bob Good evening folks. Bob here in Greensboro, NC. #lcsm |
 | Dwana Calhoun, MS (DrPH Candidate) @DeeCalhounSMHN RT @NCICancerStats: Get the stats on #LungCancer by watching our new Did You Know? Video: Get the stats on #LungCancer by watching our new Did You Know? Video: https://t.co/MnrkjeW1f2 #LCSM |
| Brendon Stiles @BrendonStilesMD Feel like I know you, @n8pennell. One day I will actually meet you in person. And be better off for it. #lcsm |
| Faces of Lung Cancer @LungCancerFaces @GeriGerim13 Hi Geri! #lcsm |
 | john @JohnLPender I'm here. #lcsm |
| Naomi @ChancesR3 @LungCancerFaces From your mouth to God’s ears! Thank you! All for the research! #lcsm |
| Faces of Lung Cancer @LungCancerFaces @n8pennell Hey, Nate! #lcsm |
| Janet Freeman-Daily @JFreemanDaily T1: @TheNCI acknowledged value of patient-driven groups focused on specific cancer mutations: https://t.co/bdAElD7jxx #LCSM |
 | Deb Smith 🌻🟧 @debsmithbeach #LCSM Deb checking in from chilly NH. Still enjoyed a lovely walk on the beach today! |
| Faces of Lung Cancer @LungCancerFaces @steele_bob Hi, Bob! #lcsm |
| Janet Freeman-Daily @JFreemanDaily Hi John, Geri and BobS! #lcsm |
| Faces of Lung Cancer @LungCancerFaces @debsmithbeach Yay! Deb's here. #lcsm |
| Janet Freeman-Daily @JFreemanDaily Hey Deb! #lcsm |
| Robert C. Doebele, MD, PhD @rdoebele osimertinib in 1st line EGFR mutant lung cancer (but still waiting for more BLOOM data for brain mets) #LCSM |
| Brendon Stiles @BrendonStilesMD T1. I love seeing immunotherapy move to early stage disease. Ground breaking study for stage III, several trials in even early stages. #lcsm |
| Robert C. Doebele, MD, PhD @rdoebele alectinib in 1st line ALK. #LCSM |
 | Sanjay Mukhopadhyay @smlungpathguy @JFreemanDaily @rdoebele Hi. Sanjay here. Lung pathologist in Cleveland. I diagnose lung cancer when a specimen is sent "to the lab" #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Howdy #lcsm https://t.co/U4oX4MmWXR |
| Naomi @ChancesR3 @JFreemanDaily Wow - beautiful! #lcsm |
| Janet Freeman-Daily @JFreemanDaily T1: Alectinib for ALK+ provides better survival than crizotinib, received FDA approval for use in untreated patients. #LCSM |
| Brendon Stiles @BrendonStilesMD T1. Also amazing to see academia/pharma continue to refine drugs for specific targets. #lcsm |
| Faces of Lung Cancer @LungCancerFaces @smlungpathguy What's better than one lung pathologist? Two! Welcome. #lcsm |
| Bob Steele @steele_bob Seems to me the social media community blossomed this year. #lcsm |
| Janet Freeman-Daily @JFreemanDaily Hi @smlungpathguy? Nice to have another pathologist drop in. #lcsm |
| #LCSM Chat @lcsmchat RT @JackWestMD: |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Happy to be here! #lcsm https://t.co/dDt7ejERPY |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T1: @TheNCI acknowledged value of patient-driven groups focused on specific cancer mutations: T1: @TheNCI acknowledged value of patient-driven groups focused on specific cancer mutations: https://t.co/bdAElD7jxx #LCSM |
| #LCSM Chat @lcsmchat RT @rdoebele: osimertinib in 1st line EGFR mutant lung cancer (but still waiting for more BLOOM data for brain mets) #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T1. I love seeing immunotherapy move to early stage disease. Ground breaking study for stage III, several trials in even early stages. #lcsm |
| #LCSM Chat @lcsmchat RT @rdoebele: alectinib in 1st line ALK. #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T1: T1: Alectinib for ALK+ provides better survival than crizotinib, received FDA approval for use in untreated patients. #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Looking forward to a great hour! #lcsm https://t.co/7V98kv3TER |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T1. Also amazing to see academia/pharma continue to refine drugs for specific targets. #lcsm |
| #LCSM Chat @lcsmchat RT @JackWestMD: |
 | Laura Greco @lgreco_ny laura here #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Thank you! #lcsm https://t.co/JJEvPo0Xzp |
| Faces of Lung Cancer @LungCancerFaces @lgreco_ny Hi, Laura! #lcsm |
| Naomi @ChancesR3 T1 biggest developments for our family were Tagrisso working for 9 months as 4th line treatment and entering combo trial to see if immunotherapy will work when comb w/ another drug. #research#hope #lcsm |
| Janet Freeman-Daily @JFreemanDaily T1: 13% increase in 2017 #LCSM tweets compared to 2016! (I looked it up on @symplur just before the chat) |
| #LCSM Chat @lcsmchat RT @JackWestMD: |
| #LCSM Chat @lcsmchat RT @ChancesR3: T1 biggest developments for our family were Tagrisso working for 9 months as 4th line treatment and entering combo trial to see if immunotherapy will work when comb w/ another drug. #research#hope #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T1: T1: 13% increase in 2017 #LCSM tweets compared to 2016! (I looked it up on @symplur just before the chat) |
| Brendon Stiles @BrendonStilesMD T1. Amazing periop results reported for Japanese and (soon) North American studies on limited resection vs. lobectomy. Still awaiting survival, but amazing to see how safely we get patients through surgery. #lcsm |
 | lysa buonanno @lysabee Hi guys!! sorry I'm late #lcsm |
| Robert C. Doebele, MD, PhD @rdoebele @JackWestMD FDA approval for all patients to get NGS is +, but making hurdle for academia & startups is going to stifle innovation #lcsm |
| Janet Freeman-Daily @JFreemanDaily T1: @CMS (Centers for Medicare and Medicaid) proposed rule for reimbursement of NGS testing for #cancer earlier this month. #lcsm |
 | Savvy Cooperative | #AskPatients @savvy_coop RT @JFreemanDaily: T1: @TheNCI acknowledged value of patient-driven groups focused on specific cancer mutations: T1: @TheNCI acknowledged value of patient-driven groups focused on specific cancer mutations: https://t.co/bdAElD7jxx #LCSM |
| Naomi @ChancesR3 @JackWestMD Yes! We are trying durvalumab as 5th line as combo - might not work but...might! #lcsm |
| Sanjay Mukhopadhyay @smlungpathguy @JFreemanDaily New to #lcsm but heard of it thru Tim and curious to see what it's all about |
 | Dr. Jan Marie Eberth @jmeberth Joining the chat from SC tonight... happy holidays to all my fellow advocates! #lcsm |
| Brendon Stiles @BrendonStilesMD Hi @lysabee. #lcsm. |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T1. Amazing periop results reported for Japanese and (soon) North American studies on limited resection vs. lobectomy. Still awaiting survival, but amazing to see how safely we get patients through surgery. #lcsm |
| Naomi @ChancesR3 @lysabee Hey Lysa! #lcsm |
| #LCSM Chat @lcsmchat RT @rdoebele: @JackWestMD FDA approval for all patients to get NGS is +, but making hurdle for academia & startups is going to stifle innovation #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T1: T1: @CMS (Centers for Medicare and Medicaid) proposed rule for reimbursement of NGS testing for #cancer earlier this month. #lcsm |
| Janet Freeman-Daily @JFreemanDaily T1: Evidence growing that SRS is better than WBR for treating #cancer brain mets (fewer long term side effects) #lcsm |
| #LCSM Chat @lcsmchat RT @ChancesR3: @JackWestMD Yes! We are trying durvalumab as 5th line as combo - might not work but...might! #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @rdoebele: @JackWestMD FDA approval for all patients to get NGS is +, but making hurdle for academia & startups is going to stifle innovation #lcsm |
| #LCSM Chat @lcsmchat RT @JackWestMD: A1) Another shift: |
| #LCSM Chat @lcsmchat RT @ChancesR3: @JackWestMD Yes! We are trying durvalumab as 5th line as combo - might not work but...might! #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: T1: T1: @CMS (Centers for Medicare and Medicaid) proposed rule for reimbursement of NGS testing for #cancer earlier this month. #lcsm |
| Janet Freeman-Daily @JFreemanDaily Hey @lysabee! How are you feeling after surgery? #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T1: T1: Evidence growing that SRS is better than WBR for treating #cancer brain mets (fewer long term side effects) #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD #hope #lcsm https://t.co/DwnVvwSwXo |
| Sanjay Mukhopadhyay @smlungpathguy RT @JackWestMD: |
| Laura Greco @lgreco_ny RT @JFreemanDaily: T1: T1: Evidence growing that SRS is better than WBR for treating #cancer brain mets (fewer long term side effects) #lcsm |
| lysa buonanno @lysabee @rdoebele Hi there! you got my tissue today. YAY!! #lcsm |
| Sanjay Mukhopadhyay @smlungpathguy RT @JackWestMD: A1) Another shift: |
| Laura Greco @lgreco_ny RT @lysabee: @rdoebele Hi there! you got my tissue today. YAY!! #lcsm |
| Bob Steele @steele_bob RT @JFreemanDaily: T1: T1: Evidence growing that SRS is better than WBR for treating #cancer brain mets (fewer long term side effects) #lcsm |
| Deb Smith 🌻🟧 @debsmithbeach @JackWestMD @lcsmchat T1 I'm a 6-yr survivor and have been happy to see more 2nd and 3rd line treatments being developed. Also, I've been on Tagrisso for over 4 yrs - amazing to see it moved to 1st line tx! #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Can't let that happen. #lcsm https://t.co/0WuncIDqxi |
| Janet Freeman-Daily @JFreemanDaily @lysabee @rdoebele Woohoo for more tissue to make ROS1 cancer models! #lcsm |
| Sanjay Mukhopadhyay @smlungpathguy RT @JFreemanDaily: T1: T1: @CMS (Centers for Medicare and Medicaid) proposed rule for reimbursement of NGS testing for #cancer earlier this month. #lcsm |
| Sanjay Mukhopadhyay @smlungpathguy RT @rdoebele: @JackWestMD FDA approval for all patients to get NGS is +, but making hurdle for academia & startups is going to stifle innovation #lcsm |
| Faces of Lung Cancer @LungCancerFaces If you're out there watching quietly, please let us know by simply tweeting #LCSM. Thanks! #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @lysabee: @rdoebele Hi there! you got my tissue today. YAY!! #lcsm |
| Robert C. Doebele, MD, PhD @rdoebele @lysabee Yes we did, kudos to ROS1ders for kickstarting remote tissue collection for cancer model building! #lcsm |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell 1) Routine use of pembro first line for high PDL1. Most of my responders are still responding! #lcsm |
| #LCSM Chat @lcsmchat RT @JackWestMD: |
| Brendon Stiles @BrendonStilesMD @JackWestMD Incredible to see how many subgroups of patients had improvement with Durva in PACIFIC. #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: @lysabee @rdoebele Woohoo for more tissue to make ROS1 cancer models! #lcsm |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell @BrendonStilesMD Same here! Hopefully will happen this year. #LCSM |
| #LCSM Chat @lcsmchat RT @lysabee: @rdoebele Hi there! you got my tissue today. YAY!! #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @lysabee @rdoebele Woohoo for more tissue to make ROS1 cancer models! #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD 2d that! #PatientsFirst #lcsm https://t.co/gdJgAAslwm |
| #LCSM Chat @lcsmchat RT @debsmithbeach: @JackWestMD @lcsmchat T1 I'm a 6-yr survivor and have been happy to see more 2nd and 3rd line treatments being developed. Also, I've been on Tagrisso for over 4 yrs - amazing to see it moved to 1st line tx! #LCSM |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: Can't let that happen. #lcsm https://t.co/0WuncIDqxi |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @n8pennell: 1) Routine use of pembro first line for high PDL1. Most of my responders are still responding! #lcsm |
| Robert C. Doebele, MD, PhD @rdoebele #LCSM how about finally new trials for EGFR and HER2 exon 20 (and new advocacy group to go with it)! |
| #LCSM Chat @lcsmchat RT @LungCancerFaces: If you're out there watching quietly, please let us know by simply tweeting #LCSM. Thanks! #lcsm |
| #LCSM Chat @lcsmchat RT @rdoebele: @lysabee Yes we did, kudos to ROS1ders for kickstarting remote tissue collection for cancer model building! #lcsm |
| Janet Freeman-Daily @JFreemanDaily T1: Entrectinib trial had promising prelim results for ROS1+ NSCLC. Has arm open for those doing well on criz but have brain mets #lcsm |
| #LCSM Chat @lcsmchat RT @n8pennell: 1) Routine use of pembro first line for high PDL1. Most of my responders are still responding! #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: @JackWestMD Incredible to see how many subgroups of patients had improvement with Durva in PACIFIC. #lcsm |
| Brendon Stiles @BrendonStilesMD @n8pennell I also personally had lots of responders (to surgery) this year who are still responding. Reason enough to celebrate. #lcsm |
 | Susan Burke Mangano @susila55 EGFR Mutations in #LungCancer: Correlation with Clinical Response to Gefitinib Therapy https://t.co/9rF6jqZ3JJ #LCSM |
| #LCSM Chat @lcsmchat RT @JackWestMD: |
| Sanjay Mukhopadhyay @smlungpathguy RT @n8pennell: 1) Routine use of pembro first line for high PDL1. Most of my responders are still responding! #lcsm |
 | Anita Figueras @scifiknitter Hello! Happy to be able to be here tonight. #lcsm |
| #LCSM Chat @lcsmchat RT @rdoebele: #LCSM how about finally new trials for EGFR and HER2 exon 20 (and new advocacy group to go with it)! |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell Proliferation of lung cancer patient groups pretty cool too #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T1: T1: Entrectinib trial had promising prelim results for ROS1+ NSCLC. Has arm open for those doing well on criz but have brain mets #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JackWestMD: Yes, broad benefit! MT @BrendonStilesMD: |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: @n8pennell I also personally had lots of responders (to surgery) this year who are still responding. Reason enough to celebrate. #lcsm |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell RT @rdoebele: #LCSM how about finally new trials for EGFR and HER2 exon 20 (and new advocacy group to go with it)! |
| Laura Greco @lgreco_ny RT @n8pennell: Proliferation of lung cancer patient groups pretty cool too #lcsm |
| lysa buonanno @lysabee @JFreemanDaily I'm feeling really good. just dealing with the drain I was hoping to avoid #lcsm |
| Janet Freeman-Daily @JFreemanDaily Yes, new patient groups formed for both EGFR Exon 20 insertions AND EGFR resistance! @rdoebele #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: @n8pennell I also personally had lots of responders (to surgery) this year who are still responding. Reason enough to celebrate. #lcsm |
| Robert C. Doebele, MD, PhD @rdoebele RT @n8pennell: 1) Routine use of pembro first line for high PDL1. Most of my responders are still responding! #lcsm |
| #LCSM Chat @lcsmchat RT @n8pennell: Proliferation of lung cancer patient groups pretty cool too #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: Yes, new patient groups formed for both EGFR Exon 20 insertions AND EGFR resistance! @rdoebele #lcsm |
| Brendon Stiles @BrendonStilesMD @n8pennell Actually think this is more than cool. Will drive education, attention, and funding. Need more. #lcsm |
| Janet Freeman-Daily @JFreemanDaily T1: Great to see increasing publicity for #lungcancer screening, and increasing efforts to decrease stigma. #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: Yes, new patient groups formed for both EGFR Exon 20 insertions AND EGFR resistance! @rdoebele #lcsm |
| Robert C. Doebele, MD, PhD @rdoebele @n8pennell but let's remember no 1st line pembro for ALK, EGFR , never smokers even if PDL1 high. #LCSM |
| Naomi @ChancesR3 @scifiknitter Hi Anita! How are you feeling? #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T1: T1: Great to see increasing publicity for #lungcancer screening, and increasing efforts to decrease stigma. #lcsm |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell Emerging trials of selective RET inhibitors! #lcsm |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell RT @rdoebele: @n8pennell but let's remember no 1st line pembro for ALK, EGFR , never smokers even if PDL1 high. #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD And #NoStigma #lcsm https://t.co/NXsxfqOxc9 |
| Janet Freeman-Daily @JFreemanDaily T2: Glad to see @NCIPrevention is talking about RISK REDUCTION for lung cancer (instead of just “prevention”) https://t.co/uFSL9QO9y3 #LCSM |
| Sanjay Mukhopadhyay @smlungpathguy RT @rdoebele: @n8pennell but let's remember no 1st line pembro for ALK, EGFR , never smokers even if PDL1 high. #LCSM |
| Laura Greco @lgreco_ny Q2) Not yet. But I have hopes. #lcsm |
| Brendon Stiles @BrendonStilesMD T1. Also pretty proud that we were able to bring @freetobreathe and @Lung_Fund together this year. 1+1=3. We all need to work together. #lcsm |
 | OurWarOnCancer @OurWarOnCancer RT @JFreemanDaily: Janet here on the Washington Coast, grabbing the last bit of sun before the winter gray skies set in #lcsm https://t.co/Le93sr0fQ7 |
| Dr. Jan Marie Eberth @jmeberth THIS! Agree that the message is starting to get out to more docs and patients. #lcsm https://t.co/OnbSbLJDhO |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD #NoStigma #PatientsFirst #lcsm https://t.co/raBaCWSbRI |
| Faces of Lung Cancer @LungCancerFaces @BrendonStilesMD @n8pennell Let's just call it totally bitchen, then, OK? #lcsm |
| OurWarOnCancer @OurWarOnCancer RT @rdoebele: Even smokers may benefit from targeted lung cancer treatments - https://t.co/Ijx4ze3pSc Kudos to Dr. Aisner and LCMC group. @CUCancerCenter #LCSM |
 | 𝘚𝘵𝘦𝘷𝘦𝘯 𝘑. 𝘋𝘶𝘧𝘧𝘪𝘦𝘭𝘥 @StevenJDuffield RT @TimAllenMDJD: #hope #lcsm https://t.co/DwnVvwSwXo |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell 2) Might need our advocates to answer the stigma question, not sure I have noticed a change but DO think there is more attention on LC than before #lcsm |
| #LCSM Chat @lcsmchat RT @JackWestMD: |
| #LCSM Chat @lcsmchat RT @rdoebele: @n8pennell but let's remember no 1st line pembro for ALK, EGFR , never smokers even if PDL1 high. #LCSM |
| #LCSM Chat @lcsmchat RT @n8pennell: Emerging trials of selective RET inhibitors! #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Big step forward. #NoStigma #lcsm https://t.co/AO5I5YtcCj |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T2: T2: Glad to see @NCIPrevention is talking about RISK REDUCTION for lung cancer (instead of just “prevention”) https://t.co/uFSL9QO9y3 #LCSM |
| Brendon Stiles @BrendonStilesMD @LungCancerFaces @n8pennell Deal. I'll stick with this. #lcsm |
| Laura Greco @lgreco_ny RT @JFreemanDaily: T2: T2: Glad to see @NCIPrevention is talking about RISK REDUCTION for lung cancer (instead of just “prevention”) https://t.co/uFSL9QO9y3 #LCSM |
| Faces of Lung Cancer @LungCancerFaces T2: Baby steps, not strides. We're in it for the long haul #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD #JustMolecularChanges #NoStigma #lcsm https://t.co/9EJINbCrrM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T1. Also pretty proud that we were able to bring @freetobreathe and @Lung_Fund together this year. 1+1=3. We all need to work together. #lcsm |
| #LCSM Chat @lcsmchat RT @jmeberth: THIS! Agree that the message is starting to get out to more docs and patients. #lcsm https://t.co/OnbSbLJDhO |
| Brendon Stiles @BrendonStilesMD T2. I think so. We owe a lot to patients (like many of you) who are putting themselves out there and helping people understand that lung cancer can affect anyone. #lcsm |
| Laura Greco @lgreco_ny RT @TimAllenMDJD: #JustMolecularChanges #NoStigma #lcsm https://t.co/9EJINbCrrM |
| OurWarOnCancer @OurWarOnCancer RT @JFreemanDaily: T1: T1: Alectinib for ALK+ provides better survival than crizotinib, received FDA approval for use in untreated patients. #LCSM |
| Naomi @ChancesR3 T2 would like to see more PSAs regarding stigma. And disappointed that ACS doesn’t do more to get rid of stigma. In fact they seem to add to public perception of smokers only for LC #lcsm |
| Dr. Jan Marie Eberth @jmeberth @BrendonStilesMD are you working at Cornell? Link on your page doesn’t seem to direct correctly. #lcsm |
| Anita Figueras @scifiknitter The EGFR Resisters are taking some big steps soon towards starting actual work. Oncs with research interest in EGFR resistance & 4th gen TKIs most welcome too join advisory committee! Contact me. #lcsm https://t.co/yI04m9EGHc |
| #LCSM Chat @lcsmchat RT @n8pennell: 2) Might need our advocates to answer the stigma question, not sure I have noticed a change but DO think there is more attention on LC than before #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Fight on! #NoStigma #lcsm #PatientsFirst https://t.co/Lme83xxOaR |
| Janet Freeman-Daily @JFreemanDaily RT @TimAllenMDJD: Big step forward. #NoStigma #lcsm https://t.co/AO5I5YtcCj |
| #LCSM Chat @lcsmchat RT @JackWestMD: |
| #LCSM Chat @lcsmchat RT @LungCancerFaces: T2: T2: Baby steps, not strides. We're in it for the long haul #lcsm |
| Laura Greco @lgreco_ny RT @LungCancerFaces: T2: T2: Baby steps, not strides. We're in it for the long haul #lcsm |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: #JustMolecularChanges #NoStigma #lcsm https://t.co/9EJINbCrrM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2. I think so. We owe a lot to patients (like many of you) who are putting themselves out there and helping people understand that lung cancer can affect anyone. #lcsm |
| #LCSM Chat @lcsmchat RT @ChancesR3: T2 would like to see more PSAs regarding stigma. And disappointed that ACS doesn’t do more to get rid of stigma. In fact they seem to add to public perception of smokers only for LC #lcsm |
| #LCSM Chat @lcsmchat RT @scifiknitter: The EGFR Resisters are taking some big steps soon towards starting actual work. Oncs with research interest in EGFR resistance & 4th gen TKIs most welcome too join advisory committee! Contact me. #lcsm https://t.co/yI04m9EGHc |
| Brendon Stiles @BrendonStilesMD @jmeberth I am.https://t.co/a9IONjjRtx Should work. #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Educate! #lcsm #NoStigma https://t.co/95RghKuGn1 |
| OurWarOnCancer @OurWarOnCancer RT @n8pennell: 1) Routine use of pembro first line for high PDL1. Most of my responders are still responding! #lcsm |
| #LCSM Chat @lcsmchat RT @JackWestMD: |
| OurWarOnCancer @OurWarOnCancer RT @BrendonStilesMD: @n8pennell I also personally had lots of responders (to surgery) this year who are still responding. Reason enough to celebrate. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @LungCancerFaces: T2: T2: Baby steps, not strides. We're in it for the long haul #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: T2. I think so. We owe a lot to patients (like many of you) who are putting themselves out there and helping people understand that lung cancer can affect anyone. #lcsm |
| lysa buonanno @lysabee @JackWestMD I feel like it is slowly changing but I wish it was faster #lcsm |
| Brendon Stiles @BrendonStilesMD T2. I am ENCOURAGED. But still a long way to go and generally uphill battle. #lcsm |
| Faces of Lung Cancer @LungCancerFaces @JackWestMD Depends on the day, Jack. #lcsm |
| lysa buonanno @lysabee @LungCancerFaces @JackWestMD true #lcsm |
| Bob Steele @steele_bob @JackWestMD Feeling very encouraged. See changes happening here in NC #lcsm |
| Janet Freeman-Daily @JFreemanDaily @JackWestMD Definitely fighting a brick wall, but seeing chinks in the bricks--some article in national media discussing #lungcancer stigma and ways to reduce it. #LCSM |
| Bob Steele @steele_bob RT @BrendonStilesMD: T2. I am ENCOURAGED. But still a long way to go and generally uphill battle. #lcsm |
| Naomi @ChancesR3 @TimAllenMDJD For sure! But need more media efforts as well. Just anyone with lungs can get lung cancer. We say it on social media all the time but need to broadcast. #lcsm |
| Brendon Stiles @BrendonStilesMD @aricaroline @JackWestMD Almost hate to say it, but I'm wondering if RT helped promote immune response? #lcsm |
| Faces of Lung Cancer @LungCancerFaces Persistence. We will win this battle against stigma. Don't know when, but it will happen as long as we don't give up. #lcsm |
| #LCSM Chat @lcsmchat RT @steele_bob: @JackWestMD Feeling very encouraged. See changes happening here in NC #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @JackWestMD Definitely fighting a brick wall, but seeing chinks in the bricks--some article in national media discussing #lungcancer stigma and ways to reduce it. #LCSM |
 | Vamsi Velcheti, MD MBA @VamsiVelcheti @n8pennell Unfortunately only 45% responses even in PDL1 high pts #LCSM need to do better |
| #LCSM Chat @lcsmchat RT @ChancesR3: @TimAllenMDJD For sure! But need more media efforts as well. Just anyone with lungs can get lung cancer. We say it on social media all the time but need to broadcast. #lcsm |
| Anita Figueras @scifiknitter RT @JackWestMD: |
| Janet Freeman-Daily @JFreemanDaily T2: Also seeing more medical orgs inviting patient/advocates to speak about patient perspectives on life with #lungcancer. #lcsm |
| #LCSM Chat @lcsmchat #LCSM https://t.co/ydaFG8n9gO |
| Anita Figueras @scifiknitter RT @BrendonStilesMD: T2. I think so. We owe a lot to patients (like many of you) who are putting themselves out there and helping people understand that lung cancer can affect anyone. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: @aricaroline @JackWestMD Almost hate to say it, but I'm wondering if RT helped promote immune response? #lcsm |
| #LCSM Chat @lcsmchat RT @LungCancerFaces: Persistence. We will win this battle against stigma. Don't know when, but it will happen as long as we don't give up. #lcsm |
| Sanjay Mukhopadhyay @smlungpathguy RT @VamsiVelchev: @n8pennell Unfortunately only 45% responses even in PDL1 high pts #LCSM need to do better |
| Deb Smith 🌻🟧 @debsmithbeach @JackWestMD @lcsmchat T2 Over this year, several people I've told about my LC ALREADY KNEW that nonsmokers are at risk! This never happened in the previous 5 yrs since dx. #LCSM |
| Brendon Stiles @BrendonStilesMD T2. The 7th graders I talked to yesterday damn sure know that never smokers can get lung cancer and that it is not the patient's "fault" either way. #lcsm |
| #LCSM Chat @lcsmchat RT @VamsiVelchev: @n8pennell Unfortunately only 45% responses even in PDL1 high pts #LCSM need to do better |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T2: T2: Also seeing more medical orgs inviting patient/advocates to speak about patient perspectives on life with #lungcancer. #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD #lcsm FTW https://t.co/IDiU1vL0Fm |
| Laura Greco @lgreco_ny RT @JFreemanDaily: T2: Also seeing more medical orgs inviting patient/advocates to speak about patient perspectives on life with #lungcancer. #lcsm Sometimes we have to claw our way in though |
| #LCSM Chat @lcsmchat RT @debsmithbeach: @JackWestMD @lcsmchat T2 Over this year, several people I've told about my LC ALREADY KNEW that nonsmokers are at risk! This never happened in the previous 5 yrs since dx. #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2. The 7th graders I talked to yesterday damn sure know that never smokers can get lung cancer and that it is not the patient's "fault" either way. #lcsm |
| Janet Freeman-Daily @JFreemanDaily @LungCancerFaces We MUST be persistent. If we #lungcancer patients/caregivers/advocates stop fighting against #stigma, who will do it? #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Progress! Thanks, #lcsm https://t.co/Ah1Gtt4vgi |
| lysa buonanno @lysabee @JFreemanDaily yes!! more are starting to. We really need to be a part of the discussions #lcsm |
| #LCSM Chat @lcsmchat RT @JackWestMD: Understand. Many think may be. RT @BrendonStilesMD: |
| Vamsi Velcheti, MD MBA @VamsiVelcheti RT @n8pennell: Emerging trials of selective RET inhibitors! #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @LungCancerFaces We MUST be persistent. If we #lungcancer patients/caregivers/advocates stop fighting against #stigma, who will do it? #lcsm |
| Brendon Stiles @BrendonStilesMD RT @lysabee: @JFreemanDaily yes!! more are starting to. We really need to be a part of the discussions #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Teach on! #lcsm #NoStigma https://t.co/JK6W7aGQIi |
| Vamsi Velcheti, MD MBA @VamsiVelcheti RT @BrendonStilesMD: T1. I love seeing immunotherapy move to early stage disease. Ground breaking study for stage III, several trials in even early stages. #lcsm |
| Naomi @ChancesR3 @BrendonStilesMD Brendan Stiles MD for president. Lol. Thank you! Im@sure they do! #LCSM. |
| Brendon Stiles @BrendonStilesMD @VamsiVelchev We missed you at DOD this year! #lcsm |
| Janet Freeman-Daily @JFreemanDaily @JackWestMD Would be interesting to count 2017 media/articles that mention #lungcancer stigma compared to even 5 years ago. #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Overdue. But great to see it happening! #lcsm https://t.co/VKmFmviMWm |
| Laura Greco @lgreco_ny RT @lysabee: @JFreemanDaily yes!! more are starting to. We really need to be a part of the discussions #lcsm |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell Or earlier stage patients benefit more #LCSM https://t.co/HIKzJo3jWM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Egad. No living with him now. #lcsm https://t.co/a4xtv4W1j2 |
| Brendon Stiles @BrendonStilesMD T3. Better drugs with less toxicity - guided by better understanding of selection. #lcsm |
| Anita Figueras @scifiknitter RT @JFreemanDaily: T2: T2: Also seeing more medical orgs inviting patient/advocates to speak about patient perspectives on life with #lungcancer. #lcsm |
| lysa buonanno @lysabee T3 more reliable blood biopsies for all mutations #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JackWestMD: |
| Bob Steele @steele_bob RT @lysabee: T3 more reliable blood biopsies for all mutations #lcsm |
| Robert C. Doebele, MD, PhD @rdoebele #LCSM Neoadjuvant trials of IO and targeted therapies becoming more mainstream. |
| Naomi @ChancesR3 @JFreemanDaily @JackWestMD Yes! Would be interesting and something we could get visual confirmation of change. #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @JackWestMD Would be interesting to count 2017 media/articles that mention #lungcancer stigma compared to even 5 years ago. #lcsm |
| Anita Figueras @scifiknitter RT @JFreemanDaily: @LungCancerFaces We MUST be persistent. If we #lungcancer patients/caregivers/advocates stop fighting against #stigma, who will do it? #lcsm |
| #LCSM Chat @lcsmchat RT @JackWestMD: |
 | jbmorgan @Janet_B_Morgan #LCSM |
| #LCSM Chat @lcsmchat RT @n8pennell: Or earlier stage patients benefit more #LCSM https://t.co/HIKzJo3jWM |
| Laura Greco @lgreco_ny t3: some clue as to ALK TKI treatment order #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. Better drugs with less toxicity - guided by better understanding of selection. #lcsm |
| #LCSM Chat @lcsmchat RT @lysabee: T3 more reliable blood biopsies for all mutations #lcsm |
| Brendon Stiles @BrendonStilesMD T3. Screening is going to increase. Going to see more sublobar resection (ahead of trials) in many cases or SBRT, both for lung sparing targeted local therapy. #lcsm |
| Naomi @ChancesR3 @TimAllenMDJD 😂😂😂 #lcsm |
| Robert C. Doebele, MD, PhD @rdoebele @lysabee agree, ctDNA not great for fusions currently #lcsm |
| #LCSM Chat @lcsmchat RT @rdoebele: #LCSM Neoadjuvant trials of IO and targeted therapies becoming more mainstream. |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD True dat #lcsm https://t.co/142oB460QE |
| #LCSM Chat @lcsmchat RT @lgreco_ny: t3: t3: some clue as to ALK TKI treatment order #lcsm |
| #LCSM Chat @lcsmchat RT @JackWestMD: |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. Screening is going to increase. Going to see more sublobar resection (ahead of trials) in many cases or SBRT, both for lung sparing targeted local therapy. #lcsm |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: True dat #lcsm https://t.co/142oB460QE |
| #LCSM Chat @lcsmchat RT @rdoebele: @lysabee agree, ctDNA not great for fusions currently #lcsm |
| Naomi @ChancesR3 RT @rdoebele: #LCSM Neoadjuvant trials of IO and targeted therapies becoming more mainstream. |
| Brendon Stiles @BrendonStilesMD T3. Promising window of opportunity trials with IO in surgically resectable patients. #lcsm |
 | CCIPD at CWRU @CCIPD_Case RT @VamsiVelchev: @n8pennell Unfortunately only 45% responses even in PDL1 high pts #LCSM need to do better |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Excellent #lcsm https://t.co/jFR0T8hLII |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JackWestMD: |
| Janet Freeman-Daily @JFreemanDaily Q3: More true partnerships between patients/caregivers/advocates/researchers/pharma to accelerate development of new #lungcancer treatments (hey, I can dream...) #LCSM |
| CCIPD at CWRU @CCIPD_Case RT @BrendonStilesMD: T1. I love seeing immunotherapy move to early stage disease. Ground breaking study for stage III, several trials in even early stages. #lcsm |
| Laura Greco @lgreco_ny RT @BrendonStilesMD: T3. Promising window of opportunity trials with IO in surgically resectable patients. #lcsm |
| Naomi @ChancesR3 RT @JFreemanDaily: Q3: Q3: More true partnerships between patients/caregivers/advocates/researchers/pharma to accelerate development of new #lungcancer treatments (hey, I can dream...) #LCSM |
| OurWarOnCancer @OurWarOnCancer RT @BrendonStilesMD: T2. The 7th graders I talked to yesterday damn sure know that never smokers can get lung cancer and that it is not the patient's "fault" either way. #lcsm |
| Brendon Stiles @BrendonStilesMD T3. More cross-discipline collaboration and combo trials. #lcsm |
| Faces of Lung Cancer @LungCancerFaces T3: A drastic uptick in early stage lung resection would be lovely and doable. #lcsm |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell RT @lgreco_ny: t3: t3: some clue as to ALK TKI treatment order #lcsm |
| Laura Greco @lgreco_ny RT @LungCancerFaces: T3: T3: A drastic uptick in early stage lung resection would be lovely and doable. #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: Q3: Q3: More true partnerships between patients/caregivers/advocates/researchers/pharma to accelerate development of new #lungcancer treatments (hey, I can dream...) #LCSM |
 | LungCancerAmerica @lcfamerica RT @IASLC: Researchers at Philadelphia's @FoxChaseCancer find link between estrogen metabolized in the lung and an increase in lung cancer among never-smokers and smokers. #LCSM https://t.co/6xLCwEbjXm |
| #LCSM Chat @lcsmchat RT @JackWestMD: |
| Vamsi Velcheti, MD MBA @VamsiVelcheti Hope to see more rationale biomarker driven combination IO trials #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. More cross-discipline collaboration and combo trials. #lcsm |
| #LCSM Chat @lcsmchat RT @LungCancerFaces: T3: T3: A drastic uptick in early stage lung resection would be lovely and doable. #lcsm |
| Robert C. Doebele, MD, PhD @rdoebele @JackWestMD agree, something for RET that actually works would be nice. #lcsm |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell 3) ctDNA emerging as effective marker for recurrence risk in early and locally advanced lung cancer #lcsm |
| Brendon Stiles @BrendonStilesMD T3. Advocacy, education, and research groups pooling resources, unifying message, and funding more ground breaking research efforts. #lcsm |
| Janet Freeman-Daily @JFreemanDaily T3: Better understanding of effective biomarkers that indicate which drugs work for whom. #lcsm |
| #LCSM Chat @lcsmchat RT @VamsiVelchev: Hope to see more rationale biomarker driven combination IO trials #lcsm |
| Naomi @ChancesR3 RT @JFreemanDaily: T3: T3: Better understanding of effective biomarkers that indicate which drugs work for whom. #lcsm |
| #LCSM Chat @lcsmchat RT @rdoebele: @JackWestMD agree, something for RET that actually works would be nice. #lcsm |
| #LCSM Chat @lcsmchat RT @n8pennell: 3) ctDNA emerging as effective marker for recurrence risk in early and locally advanced lung cancer #lcsm |
| Brendon Stiles @BrendonStilesMD T3. Improved access to care for at risk populations. #lcsm |
| Laura Greco @lgreco_ny RT @BrendonStilesMD: T3. Advocacy, education, and research groups pooling resources, unifying message, and funding more ground breaking research efforts. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. Advocacy, education, and research groups pooling resources, unifying message, and funding more ground breaking research efforts. #lcsm |
| Janet Freeman-Daily @JFreemanDaily T3: Insurance coverage of biomarker tests for actionable mutations. #lcsm |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell T3: A little more breadth of logical IO combos and fewer me-too trials #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Listen up, medical societies! #lcsm https://t.co/h4ZiUDAJ9I |
 | diseases_an @diseases_an RT @LUNGevity: Advancements are being made in #LungCancer detection and treatment to save lives and give HOPE. This is just the beginning, and it's only made possible by investing in research. Your support can help continue this momentum. Learn more here: https://t.co/zrxagSsByl #lcsm https://t.co/nCMXn2AYVS |
| Bob Steele @steele_bob RT @VamsiVelchev: Hope to see more rationale biomarker driven combination IO trials #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD #PathologistsCanHelp #lcsm https://t.co/aagWu1roYo |
| Anita Figueras @scifiknitter T3 Would love to see a human trial announcement for a 4th gen EGFR TKI. A gal can dream. #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T3: T3: Better understanding of effective biomarkers that indicate which drugs work for whom. #lcsm |
| #LCSM Chat @lcsmchat RT @JackWestMD: Sure. Big dream is for KRAS. Alas... RT @rdoebele: |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. Improved access to care for at risk populations. #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T3: T3: Insurance coverage of biomarker tests for actionable mutations. #lcsm |
| Laura Greco @lgreco_ny RT @scifiknitter: T3 Would love to see a human trial announcement for a 4th gen EGFR TKI. A gal can dream. #lcsm |
| #LCSM Chat @lcsmchat RT @n8pennell: T3: T3: A little more breadth of logical IO combos and fewer me-too trials #lcsm |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: Listen up, medical societies! #lcsm https://t.co/h4ZiUDAJ9I |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell 3) Agree, emerging effective targeted treatments for HER2, EGFR exon 20, RET would be wonderful #lcsm |
| Janet Freeman-Daily @JFreemanDaily T3: Increasing use of Patient Reported Outcomes in clinical trials to capture impact of toxicities and treatment regimens #lcsm |
| Naomi @ChancesR3 RT @scifiknitter: T3 Would love to see a human trial announcement for a 4th gen EGFR TKI. A gal can dream. #lcsm |
| #LCSM Chat @lcsmchat RT @scifiknitter: T3 Would love to see a human trial announcement for a 4th gen EGFR TKI. A gal can dream. #lcsm |
| Naomi @ChancesR3 RT @JFreemanDaily: T3: T3: Increasing use of Patient Reported Outcomes in clinical trials to capture impact of toxicities and treatment regimens #lcsm |
| #LCSM Chat @lcsmchat RT @JackWestMD: |
| #LCSM Chat @lcsmchat RT @n8pennell: 3) Agree, emerging effective targeted treatments for HER2, EGFR exon 20, RET would be wonderful #lcsm |
| Vamsi Velcheti, MD MBA @VamsiVelcheti Hope to see more funding for scientifically rationale NCI-Academic-Coop led clinical trials #lcsm |
| Brendon Stiles @BrendonStilesMD RT @JFreemanDaily: T3: T3: Increasing use of Patient Reported Outcomes in clinical trials to capture impact of toxicities and treatment regimens #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T3: T3: Increasing use of Patient Reported Outcomes in clinical trials to capture impact of toxicities and treatment regimens #lcsm |
| Janet Freeman-Daily @JFreemanDaily T3: Maybe progress in identifying blood biomarkers of progression outside of scans? #lcsm |
| Brendon Stiles @BrendonStilesMD @VamsiVelchev Indeed. Glaring need. #lcsm |
| #LCSM Chat @lcsmchat RT @VamsiVelchev: Hope to see more funding for scientifically rationale NCI-Academic-Coop led clinical trials #lcsm |
| Laura Greco @lgreco_ny t3: Drastically more funding for lung cancer research. Why not? #lcsm |
| Anita Figueras @scifiknitter RT @lgreco_ny: t3: t3: some clue as to ALK TKI treatment order #lcsm |
| Janet Freeman-Daily @JFreemanDaily @JackWestMD The CMS Notice of Coverage Determination for NGS tests will have more impact--and it has some issues. #lcsm |
| Vamsi Velcheti, MD MBA @VamsiVelcheti RT @JFreemanDaily: T3: T3: Increasing use of Patient Reported Outcomes in clinical trials to capture impact of toxicities and treatment regimens #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Requires #EvidenceBasedMedicine #efficacy , and rational health care policy. #lcsm https://t.co/gZscafcKuv |
| Brendon Stiles @BrendonStilesMD @scifiknitter Dreams lead to action. #lcsm |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell RT @JackWestMD: |
| Anita Figueras @scifiknitter RT @JFreemanDaily: T3: T3: Insurance coverage of biomarker tests for actionable mutations. #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Should #lcsm https://t.co/Vsm0ryzC4h |
| Anita Figueras @scifiknitter RT @BrendonStilesMD: T3. Advocacy, education, and research groups pooling resources, unifying message, and funding more ground breaking research efforts. #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: T3: T3: Maybe progress in identifying blood biomarkers of progression outside of scans? #lcsm |
| #LCSM Chat @lcsmchat RT @JackWestMD: Shouldn't FDA approval facilitate that greatly? RT @JFreemanDaily: T3: |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T3: T3: Maybe progress in identifying blood biomarkers of progression outside of scans? #lcsm |
| #LCSM Chat @lcsmchat RT @lgreco_ny: t3: t3: Drastically more funding for lung cancer research. Why not? #lcsm |
| Vamsi Velcheti, MD MBA @VamsiVelcheti RT @JackWestMD: |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @JackWestMD The CMS Notice of Coverage Determination for NGS tests will have more impact--and it has some issues. #lcsm |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: Requires #EvidenceBasedMedicine #efficacy , and rational health care policy. #lcsm https://t.co/gZscafcKuv |
| Anita Figueras @scifiknitter RT @BrendonStilesMD: T3. Improved access to care for at risk populations. #lcsm |
| Vamsi Velcheti, MD MBA @VamsiVelcheti RT @lgreco_ny: t3: t3: Drastically more funding for lung cancer research. Why not? #lcsm |
| #LCSM Chat @lcsmchat RT @JackWestMD: Yes! moving lab data to clin validat'n more than case study here & there. RT @lgreco_ny: t3: |
| Anita Figueras @scifiknitter RT @JFreemanDaily: Q3: Q3: More true partnerships between patients/caregivers/advocates/researchers/pharma to accelerate development of new #lungcancer treatments (hey, I can dream...) #LCSM |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell Yes! Would be nice to have some overarching goal setting and not everyone running to develop their own drugs #LCSM https://t.co/UYkzs5XRFX |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Absolutely. #lcsm https://t.co/rF0kqI9QZF |
| Faces of Lung Cancer @LungCancerFaces Federal research funding must be equitable! #433aDay RT @lgreco_ny: t3: Drastically more funding for lung cancer research. Why not? #lcsm |
| Bob Steele @steele_bob RT @lgreco_ny: t3: t3: Drastically more funding for lung cancer research. Why not? #lcsm |
| Anita Figueras @scifiknitter RT @JackWestMD: |
| #LCSM Chat @lcsmchat RT @n8pennell: Yes! Would be nice to have some overarching goal setting and not everyone running to develop their own drugs #LCSM https://t.co/UYkzs5XRFX |
| Laura Greco @lgreco_ny RT @LungCancerFaces: Federal research funding must be equitable! #433aDay RT @lgreco_ny: t3: Federal research funding must be equitable! #433aDay RT @lgreco_ny: t3: Drastically more funding for lung cancer research. Why not? #lcsm |
| #LCSM Chat @lcsmchat RT @JackWestMD: |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell RT @JackWestMD: |
| Vamsi Velcheti, MD MBA @VamsiVelcheti RT @LungCancerFaces: Federal research funding must be equitable! #433aDay RT @lgreco_ny: t3: Federal research funding must be equitable! #433aDay RT @lgreco_ny: t3: Drastically more funding for lung cancer research. Why not? #lcsm |
| #LCSM Chat @lcsmchat RT @LungCancerFaces: Federal research funding must be equitable! #433aDay RT @lgreco_ny: t3: Federal research funding must be equitable! #433aDay RT @lgreco_ny: t3: Drastically more funding for lung cancer research. Why not? #lcsm |
| Janet Freeman-Daily @JFreemanDaily T3: Wider use of molecular tumor boards that enable community doctors to pick best treatment option for patients #lcsm |
| Bob Steele @steele_bob RT @LungCancerFaces: Federal research funding must be equitable! #433aDay RT @lgreco_ny: t3: Federal research funding must be equitable! #433aDay RT @lgreco_ny: t3: Drastically more funding for lung cancer research. Why not? #lcsm |
| lysa buonanno @lysabee @LungCancerFaces @lgreco_ny this is a BIG NEED #lcsm |
| Bob Steele @steele_bob RT @JFreemanDaily: T3: T3: Wider use of molecular tumor boards that enable community doctors to pick best treatment option for patients #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD But #FreeMarket #FreeEnterprise #Competition #lcsm https://t.co/gPHcnZuU25 |
| Laura Greco @lgreco_ny RT @lysabee: @LungCancerFaces @lgreco_ny this is a BIG NEED #lcsm |
 | Paula A @paulalv RT @LungCancerFaces: Federal research funding must be equitable! #433aDay RT @lgreco_ny: t3: Federal research funding must be equitable! #433aDay RT @lgreco_ny: t3: Drastically more funding for lung cancer research. Why not? #lcsm |
| Brendon Stiles @BrendonStilesMD @Lung_Fund is going to revamp our grant portfolio and continue to fund critical high reward projects. Hoping to engage patients more through @freetobreathe merger. #lcsm |
 | Kirsten Cagle @KirstenCagle1 #lcsm There was a stigma to even researching the early detection and diagnosis of lung cancer as @TimAllenMDJD can attest to my pissed off self about ribbons, cakes, pink socks etc used to profit from illness. I have respect for these patients, & it has been our honor to serve. |
| Naomi @ChancesR3 RT @lgreco_ny: t3: t3: Drastically more funding for lung cancer research. Why not? #lcsm |
| Janet Freeman-Daily @JFreemanDaily T3: More research into #lungcancer patient experience #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T3: T3: Wider use of molecular tumor boards that enable community doctors to pick best treatment option for patients #lcsm |
| Vamsi Velcheti, MD MBA @VamsiVelcheti RT @TimAllenMDJD: Listen up, medical societies! #lcsm https://t.co/h4ZiUDAJ9I |
| Anita Figueras @scifiknitter RT @lgreco_ny: t3: t3: Drastically more funding for lung cancer research. Why not? #lcsm |
| Janet Freeman-Daily @JFreemanDaily T3: More patients having access to true #palliativecare during active treatment #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD #NoStigma #NumberOneCancerKiller #lcsm https://t.co/RCNmrZUpJP |
| Vamsi Velcheti, MD MBA @VamsiVelcheti RT @BrendonStilesMD: @Lung_Fund is going to revamp our grant portfolio and continue to fund critical high reward projects. Hoping to engage patients more through @freetobreathe merger. #lcsm |
| #LCSM Chat @lcsmchat RT @KirstenCagle1: #lcsm There was a stigma to even researching the early detection and diagnosis of lung cancer as @TimAllenMDJD can attest to my pissed off self about ribbons, cakes, pink socks etc used to profit from illness. I have respect for these patients, & it has been our honor to serve. |
| Anita Figueras @scifiknitter RT @TimAllenMDJD: Requires #EvidenceBasedMedicine #efficacy , and rational health care policy. #lcsm https://t.co/gZscafcKuv |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @KirstenCagle1: #lcsm There was a stigma to even researching the early detection and diagnosis of lung cancer as @TimAllenMDJD can attest to my pissed off self about ribbons, cakes, pink socks etc used to profit from illness. I have respect for these patients, & it has been our honor to serve. |
| Vamsi Velcheti, MD MBA @VamsiVelcheti RT @n8pennell: Yes! Would be nice to have some overarching goal setting and not everyone running to develop their own drugs #LCSM https://t.co/UYkzs5XRFX |
| Faces of Lung Cancer @LungCancerFaces @KirstenCagle1 @TimAllenMDJD As Tim knows, I liked pissed off! #lcsm |
| Brendon Stiles @BrendonStilesMD Have to sign off. The energy of the group is always amazing. I am proud to be a part of #lcsm. Thanks for another great year! |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: @Lung_Fund is going to revamp our grant portfolio and continue to fund critical high reward projects. Hoping to engage patients more through @freetobreathe merger. #lcsm |
| Vamsi Velcheti, MD MBA @VamsiVelcheti RT @n8pennell: T3: T3: A little more breadth of logical IO combos and fewer me-too trials #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T3: T3: More research into #lungcancer patient experience #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T3: T3: More patients having access to true #palliativecare during active treatment #lcsm |
| Anita Figueras @scifiknitter RT @LungCancerFaces: Federal research funding must be equitable! #433aDay RT @lgreco_ny: t3: Federal research funding must be equitable! #433aDay RT @lgreco_ny: t3: Drastically more funding for lung cancer research. Why not? #lcsm |
| lysa buonanno @lysabee @BrendonStilesMD happy holiday Brendon #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD #LikeABoss #lcsm https://t.co/l3XjqYClEM |
| Dr. Jan Marie Eberth @jmeberth And more access to pulmonary rehab for LC survviors. #lcsm https://t.co/M7n1FP2g2e |
 | Karen Loss @cancertrek RT @BrendonStilesMD: T2. The 7th graders I talked to yesterday damn sure know that never smokers can get lung cancer and that it is not the patient's "fault" either way. #lcsm |
| Paula A @paulalv RT @JFreemanDaily: T3: T3: More research into #lungcancer patient experience #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @jmeberth: And more access to pulmonary rehab for LC survviors. #lcsm https://t.co/M7n1FP2g2e |
| Janet Freeman-Daily @JFreemanDaily RT @jmeberth: And more access to pulmonary rehab for LC survviors. #lcsm https://t.co/M7n1FP2g2e |
| Anita Figueras @scifiknitter RT @BrendonStilesMD: @Lung_Fund is going to revamp our grant portfolio and continue to fund critical high reward projects. Hoping to engage patients more through @freetobreathe merger. #lcsm |
| Faces of Lung Cancer @LungCancerFaces T4: From an advocacy standpoint, how to break out of our bubble, avoid the echo chamber problem. #lcsm |
| #LCSM Chat @lcsmchat RT @JackWestMD: |
| Janet Freeman-Daily @JFreemanDaily RT @LungCancerFaces: T4: T4: From an advocacy standpoint, how to break out of our bubble, avoid the echo chamber problem. #lcsm |
| Anita Figueras @scifiknitter RT @JFreemanDaily: T3: T3: More patients having access to true #palliativecare during active treatment #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Have a safe and pleasant holiday season. #lcsm https://t.co/AfkcBI4LvJ |
| #LCSM Chat @lcsmchat RT @jmeberth: And more access to pulmonary rehab for LC survviors. #lcsm https://t.co/M7n1FP2g2e |
| Laura Greco @lgreco_ny t4: we as patients need to expect and demand better from those that purport to represent us or work for us. WE deserve better. #lcsm |
| Paula A @paulalv RT @jmeberth: And more access to pulmonary rehab for LC survviors. #lcsm https://t.co/M7n1FP2g2e |
| #LCSM Chat @lcsmchat RT @LungCancerFaces: T4: T4: From an advocacy standpoint, how to break out of our bubble, avoid the echo chamber problem. #lcsm |
| Anita Figueras @scifiknitter RT @jmeberth: And more access to pulmonary rehab for LC survviors. #lcsm https://t.co/M7n1FP2g2e |
| Laura Greco @lgreco_ny RT @JackWestMD: |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell T4) Would like to work on growing the community on SM #lcsm |
| Janet Freeman-Daily @JFreemanDaily T4: Patient advocates need to refine our story-telling skills to be focused, concise, and bring HOPE in a way that attracts the media #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Attn: health care policymakers #lcsm https://t.co/Hqi4bOfa7b |
| Bob Steele @steele_bob RT @JFreemanDaily: T4: T4: Patient advocates need to refine our story-telling skills to be focused, concise, and bring HOPE in a way that attracts the media #lcsm |
| #LCSM Chat @lcsmchat RT @lgreco_ny: t4: t4: we as patients need to expect and demand better from those that purport to represent us or work for us. WE deserve better. #lcsm |
| Anita Figueras @scifiknitter RT @JackWestMD: |
| #LCSM Chat @lcsmchat RT @JackWestMD: |
| #LCSM Chat @lcsmchat RT @n8pennell: T4) Would like to work on growing the community on SM #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T4: T4: Patient advocates need to refine our story-telling skills to be focused, concise, and bring HOPE in a way that attracts the media #lcsm |
| Bob Steele @steele_bob RT @JackWestMD: |
| Janet Freeman-Daily @JFreemanDaily Agree @n8pennell. Need to make better use of other social media tools. Perhaps some live patient-doc video chats or podcasts? #lcsm |
 | Bilal Piperdi @bpiperdi RT @n8pennell: 1) Routine use of pembro first line for high PDL1. Most of my responders are still responding! #lcsm |
| Janet Freeman-Daily @JFreemanDaily @TimAllenMDJD You too! #lcsm |
| #LCSM Chat @lcsmchat RT @JackWestMD: |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Refined or not, just please tell your honest and compelling stories! #FromTheHeart #PatientsFirst #hope https://t.co/7GvOtobyTY |
| Janet Freeman-Daily @JFreemanDaily T4: Find more ways that patients can help researchers accelerate their work. #lcsm |
| Naomi @ChancesR3 RT @JFreemanDaily: T4: T4: Patient advocates need to refine our story-telling skills to be focused, concise, and bring HOPE in a way that attracts the media #lcsm |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell Yes we could work together beyond Twitter. #LCSM peeps doing editorials, media interviews/videos/blogs/podcasts together. https://t.co/dU5YYGPBVj |
| Janet Freeman-Daily @JFreemanDaily RT @JackWestMD T4) I think we want to be positive as a community & not be perceived as always feeling slighted (even if it's fair to). #lcsm |
| Faces of Lung Cancer @LungCancerFaces I'm sorry, I have to bug out early. Have a happy hanukkah, Merry Christmas, Kwanzaa, Festivus, whatever you like! See you in 2018! xo #lcsm |
| Dr. Jan Marie Eberth @jmeberth And rural patients... need better access to specialists. #lcsm https://t.co/jMB2suaZvk |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Stay positive and tell your stories. #lcsm https://t.co/t3QtoQegmx |
| Naomi @ChancesR3 @TimAllenMDJD Yup! I love it when you do that. 😂#lcsm |
 | Sally James @jamesian @JFreemanDaily Agree so much with this - but it isn't easy to do. #lcsm https://t.co/RTUz4pQT9A |
| Bob Steele @steele_bob RT @JFreemanDaily: RT @JackWestMD T4) I think we want to be positive as a community & not be perceived as always feeling slighted (even if it's fair to). #lcsm |
| Bob Steele @steele_bob RT @jmeberth: And rural patients... need better access to specialists. #lcsm https://t.co/jMB2suaZvk |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell Wonder if we could get some non-LCSM Twitter superstars to join the Tweetchat once in a while and expand the audience... #lcsm |
| Anita Figueras @scifiknitter Yes! There are patients with great skills who want to help but we are not sure how. The ROS1ders are the best current model, but we need the experts to open the door with us and tell us what they need. #lcsm https://t.co/C1pfN4b2O5 |
| Deb Smith 🌻🟧 @debsmithbeach @LungCancerFaces Happy new year too! Take care of yourself. #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T4: T4: Find more ways that patients can help researchers accelerate their work. #lcsm |
| #LCSM Chat @lcsmchat RT @n8pennell: Yes we could work together beyond Twitter. #LCSM peeps doing editorials, media interviews/videos/blogs/podcasts together. https://t.co/dU5YYGPBVj |
| Janet Freeman-Daily @JFreemanDaily @jamesian "Isn't easy to do" -- Amen to that #LCSM |
 | Kathleen D. Hoffman @drkdhoffman #LCSM Join us in 10 mins for #PTSD & #cancer discussion use #LateEffects |
 | Jessica G.Y. Luc, MD @JessicaLuc1 Reading along and learning a lot. Thanks for this great community #LCSM |
| #LCSM Chat @lcsmchat RT @jmeberth: And rural patients... need better access to specialists. #lcsm https://t.co/jMB2suaZvk |
| Anita Figueras @scifiknitter RT @n8pennell: Yes we could work together beyond Twitter. #LCSM peeps doing editorials, media interviews/videos/blogs/podcasts together. https://t.co/dU5YYGPBVj |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD They deserve the same excellent diagnoses and treatments. #lcsm https://t.co/tVGsvq4VU8 |
| #LCSM Chat @lcsmchat RT @n8pennell: Wonder if we could get some non-LCSM Twitter superstars to join the Tweetchat once in a while and expand the audience... #lcsm |
| #LCSM Chat @lcsmchat RT @scifiknitter: Yes! There are patients with great skills who want to help but we are not sure how. The ROS1ders are the best current model, but we need the experts to open the door with us and tell us what they need. #lcsm https://t.co/C1pfN4b2O5 |
 | SunSource Pharma @SunsourcePharma RT @Roche: |
| Anita Figueras @scifiknitter RT @jmeberth: And rural patients... need better access to specialists. #lcsm https://t.co/jMB2suaZvk |
| #LCSM Chat @lcsmchat RT @JackWestMD: |
| Robert C. Doebele, MD, PhD @rdoebele Thanks to all for the work you do in your own individual way. Here's to a great 2018! #lcsm |
| Dr. Jan Marie Eberth @jmeberth We did research on #lungcancer tweets and highlight #LCSM specifically. https://t.co/ZMsdB6dbAZ https://t.co/VDuQv1QCps |
| Naomi @ChancesR3 RT @JackWestMD: CT (2): |
| Janet Freeman-Daily @JFreemanDaily Hope all of the #LCSM Community has more joy, meaning, and good living in 2018! Thanks for contributing your time & talent to #LCSM. |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell It feels like there is momentum building, real hope for patients with LC. You are all a part of that and hopefully will only accelerate in 2018! #lcsm |
| Vamsi Velcheti, MD MBA @VamsiVelcheti RT @JackWestMD: CT (2): |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD 2017 has been an unprecedented year for lung cancer discoveries, understanding, and expanding treatment options. #hope #PatientsFirst #NoStigma #lcsm https://t.co/bod0tKxR7W |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell RT @jmeberth: We did research on #lungcancer tweets and highlight #LCSM specifically. https://t.co/ZMsdB6dbAZ https://t.co/VDuQv1QCps |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: Hope all of the #LCSM Community has more joy, meaning, and good living in 2018! Thanks for contributing your time & talent to #LCSM. |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @n8pennell: It feels like there is momentum building, real hope for patients with LC. You are all a part of that and hopefully will only accelerate in 2018! #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JackWestMD: CT: |
| Bob Steele @steele_bob Really glad to be part of our LCSM community. Helps me get reenergized. Wish everyone Happy Hanukkah Merry Christmas & Happy New Year! #lcsm |
| #LCSM Chat @lcsmchat RT @JackWestMD: CT: |
| Anita Figueras @scifiknitter CT The passion and info sharing by the medical pros who participate in #lcsm always leaves me with hope of continued progress. Thanks so much for caring and working so hard to save/extend our lives, and for talking with us. |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD It has been a privilege to participate. #lcsm https://t.co/Jv3FQ8TZzr |
| #LCSM Chat @lcsmchat RT @JackWestMD: CT (2): |
| #LCSM Chat @lcsmchat RT @jmeberth: We did research on #lungcancer tweets and highlight #LCSM specifically. https://t.co/ZMsdB6dbAZ https://t.co/VDuQv1QCps |
| Deb Smith 🌻🟧 @debsmithbeach Thanks to all of us working to make things better, Drs, RNs, researchers, patients, advocates, etc! Enjoy your holidays and happy new year! #LCSM |
| #LCSM Chat @lcsmchat RT @n8pennell: It feels like there is momentum building, real hope for patients with LC. You are all a part of that and hopefully will only accelerate in 2018! #lcsm |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: 2017 has been an unprecedented year for lung cancer discoveries, understanding, and expanding treatment options. #hope #PatientsFirst #NoStigma #lcsm https://t.co/bod0tKxR7W |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: Hope all of the #LCSM Community has more joy, meaning, and good living in 2018! Thanks for contributing your time & talent to #LCSM. |
| #LCSM Chat @lcsmchat RT @scifiknitter: CT The passion and info sharing by the medical pros who participate in #lcsm always leaves me with hope of continued progress. Thanks so much for caring and working so hard to save/extend our lives, and for talking with us. |
| #LCSM Chat @lcsmchat RT @steele_bob: Really glad to be part of our LCSM community. Helps me get reenergized. Wish everyone Happy Hanukkah Merry Christmas & Happy New Year! #lcsm |
| Bob Steele @steele_bob See you all next year! #lcsm |
| #LCSM Chat @lcsmchat RT @JackWestMD: |
| Janet Freeman-Daily @JFreemanDaily RT @jmeberth: We did research on #lungcancer tweets and highlight #LCSM specifically. https://t.co/ZMsdB6dbAZ https://t.co/VDuQv1QCps |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell Happy Holidays all and see you in the New Year! #lcsm |
| Janet Freeman-Daily @JFreemanDaily @jmeberth Thanks for highlighting #LCSM's contribution to #lungcancer social media! #lcsm |
 | Heidi Grabenstatter @PatientIntv RT @JFreemanDaily: T1: @TheNCI acknowledged value of patient-driven groups focused on specific cancer mutations: T1: @TheNCI acknowledged value of patient-driven groups focused on specific cancer mutations: https://t.co/bdAElD7jxx #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @JackWestMD: CT (2): |
| Deb Smith 🌻🟧 @debsmithbeach RT @n8pennell: It feels like there is momentum building, real hope for patients with LC. You are all a part of that and hopefully will only accelerate in 2018! #lcsm |
| Janet Freeman-Daily @JFreemanDaily @rdoebele Thanks for joining #LCSM Chat! Appreciated your contributions about advancements for #lungcancer treatments. |
| Bob Steele @steele_bob RT @scifiknitter: CT The passion and info sharing by the medical pros who participate in #lcsm always leaves me with hope of continued progress. Thanks so much for caring and working so hard to save/extend our lives, and for talking with us. |
| Janet Freeman-Daily @JFreemanDaily RT @rdoebele: #LCSM Neoadjuvant trials of IO and targeted therapies becoming more mainstream. |
| Janet Freeman-Daily @JFreemanDaily RT @n8pennell: 1) Routine use of pembro first line for high PDL1. Most of my responders are still responding! #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @rdoebele: #LCSM how about finally new trials for EGFR and HER2 exon 20 (and new advocacy group to go with it)! |
| Deb Smith 🌻🟧 @debsmithbeach RT @TimAllenMDJD: 2017 has been an unprecedented year for lung cancer discoveries, understanding, and expanding treatment options. #hope #PatientsFirst #NoStigma #lcsm https://t.co/bod0tKxR7W |
| Janet Freeman-Daily @JFreemanDaily RT @rdoebele: alectinib in 1st line ALK. #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @rdoebele: osimertinib in 1st line EGFR mutant lung cancer (but still waiting for more BLOOM data for brain mets) #LCSM |
 | Ari Caroline @aricaroline @JackWestMD I only happen upon #lcsm by serendipity but it’s really a tremendous service to the community. Thank you for organizing! |
 | Enlightening Results 💡 @GraceCordovano RT @JFreemanDaily: T4: T4: Patient advocates need to refine our story-telling skills to be focused, concise, and bring HOPE in a way that attracts the media #lcsm |
| Janet Freeman-Daily @JFreemanDaily #LCSM Outstanding ORR and DoR/PFS for entrectinib in ROS1+ #NSCLC #ROS1 @ros1cancer https://t.co/hvh2x7JJIt |
#LCSM content from Twitter.